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Abstract
Background: Cervical cancer is a major public health problem worldwide. While Romania has the highest
incidence of cervical cancer in Europe, the prevalence of HPV has not been evaluated. We report the first data on
HPV prevalence and type distribution in Northeast Romania.
Methods: HPV prevalence and genotype distribution was investigated in 514 consecutively women with or
without cervical lesions in Northeast Romania. Genotyping was performed with Linear Array Genotyping/Roche kit.
Results: In our study group, 192/514 (37.4%) patients were positive for HPV (infected with single and with multiple
HPV types). Most frequent types were: 16 (10.5%), 53 (5.44%), 51 (5.05%), 52 (4.08%) 18 (2.91%) and 31 (2.73%).
Conclusions: Infection with high risk types of HPV is common in Northeast Romania. Enhanced and systematic
screening for cervical cancer is needed. Our results call for the implementation of a National HPV vaccine program
in Romania.
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Background
Human Papilloma Virus (HPV) is the necessary cause of
cervical cancer [1] and several screening methods have
been developed to assess its prevalence in risk groups or
patients [2] Although 15 HPV types are associated with
high risk (HR) for cervical cancer, two HPV types, 16
and 18, account for 70% of cervical cancer cases [3].
Each HR HPV type associates different carcinogenetic
risks [4]. Using HPV/DNA genotyping tests can inform
on the natural history of HPV infection by type and col-
lectively, determine incidence, prevalence, and progres-
sion of HPV infection. Furthermore, screening for a
broad array of HPV types can inform decisions on the
need for HPV vaccine in a given population and enable
early detection of women who are infected with HPV
and at risk for cervical cancer.
Romania has the highest incidence of cancer in Eur-
ope, with an incidence of 23.9/100,000 [5]. In Romania,
systematic screening for cervical cancer (i.e., cytology or
HPV/DNA testing) is not available. Furthermore, no
data on HPV genotype prevalence in Romania is avail-
able [6]. A government attempt in 2009 to implement
HPV vaccination in Romanian young girls failed because
of the lack of medical information on the prevalence of
HPV genotypes.
The goal of this study was to establish HPV preva-
lence and genotype distribution in women with and
without cervical lesions in Northeast Romania (a popu-
lation of 4.5 million people) in an attempt to gather suf-
ficient information to support future vaccination
program.
Results and discussion
After 2 years of systematic testing the following results
were obtained in our study group with regards to classi-
cal risk factors for developing cervical cancer: 71/514
(13.8%) of interviewed subjects declared use of oral con-
traceptives; 146/514 (28.4%) had other gynecologic
infections (Neisseria gonorrhoeae, Candida spp, Tricho-
monas vaginalis, Treponema pallidum); 85/514 (16.5%)
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declared having more than three sexual partners. Papa-
nicolau smear test results were as follows: ASCUS - 71/
514 (13.8%), ASCH - 49/514 (9.5%), LGSIL - 107/514
(20.8%), HGSIL - 41/514 (8.0%), inflammatory - 31/514
(6.0%) while a normal Pat test was reported for 164/514
(31.9%) patients. Note that 51/514 (9.9%) did not had
any cytology examination prior to the study, while pre-
senting with macroscopic and colposcopic suspicion for
H P Vi n f e c t i o n .T h e s er e s u l t sa r ec o m p a r a b l et ot h o s e
reported in other regions of Romania [7].
The overall testing of the samples in our study gave
the following relative prevalence results: out of the total
514 tested samples, 192 (37.3%) samples were positive
for HPV/DNA, 120 of which (23.3%) were single HPV
type infections and 72 (14%) tested positive for multiple
HPV types (Table 1).
HR HPV types were detected in 8/108 (7.42%) of
women with no Pap test and in different percent for
patients with Pap smear scores: 15/108 (13.9%) ASCUS,
16/108 (14.8%) ASC-H, 19/108 (17.6%) LGSI, 21/108
(19.4%) HGSIL and 7/108 (6.5%) having “inflammatory”
cytological result. In 22/108 (20.4%) cases positive for
HR HPV, the result of conventional smear was reported
as “normal” (Figure 1)
Since the relative prevalence of different HPV type
may inform the composition of the polyvalent vaccine in
a given region, we focused on the eight first HPV types
detected that were HPV 16, 53, 51, 52, 18, 31, CP6108,
6 and HPV 42. The highest prevalence for multiple
HPV type infection was observed in the age group of
21-30 years: 19/40 (47.5%), while women in the age
group of 31-40 years had the highest prevalence of HR
HPV types: 40/108 (37%). Of all the HR HPV positive
women detected, 20/71 (18.5%) declared use of oral con-
traceptives, 32/146 (29.6%) had associated gynecological
pathology, 31/85 (28.7%) reported cigarette smoking and
16/53 (14.8%) reported more than 3 sexual partners. Of
all the DNA/HPV negative women, 11.3% declared use
of oral contraceptives, 27% had associated gynecological
pathology, 12.6% reported cigarette smoking and 5.5%
reported more than 3 sexual partners.
Multiple HPV types infections were found in 8/72
(11.1%) persons who were never tested for Papanicolau
cytology and 20/72 (27.8%) women with normal result.
For patients that received other scores, these percents
varied between 5.6 and 20.8%. One explanation for
detecting DNA/HPV in women with normal cytology is
that the majority of HPV infections are transient.
In the group of patients that were tested for cytologic
examination, we have detected 18/51 (35.3%) positive
with HR HPV (high risk oncogenic types), pHR HPV
(probable high risk types), LR HPV (low risk oncogenic
types) and multiple HPV type infections [8]
The prevalence of HPV genotypes included in the
quadrivalent vaccine was as follows: HPV type 16-10.5%
(54/514), HPV type 18-2.91% (15/514), HPV type 6-
2.33% (12/514) and HPV type 11-0.19% (1/514).
Women identified to carry with HR HPV infection
will follow the European Guidelines for quality assur-
ance in cervical cancer screening (2008): if the cytology
is normal, they will repeat the HPV DNA test after 6-
12 month; if they present with an abnormal Pap
smear, they will be monitored by repetition of the
smear, and referral for colposcopy. Women with HR
HPV and HGSIL usually are candidate for excisional
procedures, but the choice of treatment for women
with HSIL will depend on the suspected diagnosis, the
size and type of transformation zone, age and fertility
aspirations [9].
The relative prevalence of HPV types was similar in
patients infected with single genotypes and in those
with multiple infections. Multiple infections were pro-
duced by two to eight genotypes per sample. Note that
these results may be due to either a numerous reexpo-
sure rate or to a high sensitivity of the assay used in our
study in comparison to other HPV genotyping techni-
ques (INNO LiPA, Reverse Line Blot) [10]. In order for
the typing to meaningful, quality control and standar-
dized panels of samples would need to be implemented
for the regional reference laboratories [11].
Table 1 The prevalence of HPV genotypes for all
infections
HPV TYPE Frequency Percent
NEGATIVE 322 62,6
16 54 10,5
53 28 5,44
51 26 5,05
52 21 4,08
18 15 2,91
31 14 2,73
CP6108 13 2,52
6, 45 * 12 2,33
33 11 2,14
42 10 1,94
58, 9 1,75
68, 73 * 8 1,55
66 7 1,36
84 6 1,16
62, 70* 5 0,97
82 4 0,77
55 3 0,58
56 2 0,38
11, 35, 39, 40, 61, IS39 * 1 0,19
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Page 2 of 5Thus, our study identified a high prevalence of HPV
infection associated with cervical cancer in our area and
therefore supports implementation of primary preven-
tion of cervical cancer by vaccination in Northeast
Romania, and in all country as well.
In our region, screening of cervical cancer is not sys-
tematic and the quality control guidelines for conven-
tional smears are not implemented [12]. Additionally,
general population lack knowledge regarding connection
between HPV and cervical cancer and necessity of per-
forming regular screening for detecting precancerous
cervical lesions [13]. However, as supported by our
study, a systematic testing for HPV both in general
population as well as in gynecological patients has to
potential to significantly reduce the rates of cervical
cancer and therefore a strategy for systematic screening
is badly needed.
It is considered that full spectrum genotyping is useful
for evaluation HPV epidemiology, and to the study of
the impact of HPV vaccination and for clinical practice,
to assess the persistence of HPV infection: stratification
of risk for CIN 2+, ASCUS follow-up or treatment fol-
low up. However, in Romania, similar to numerous
other nations, screening for cervical cancer is not sys-
tematic and even conventional smear is not done on a
regular basis [12]. In addition, cytology has a lowest sen-
sitivity in comparison with DNA/HPV tests (53% versus
96%) [14]. This calls for an alternative strategy consist-
ing of improving the infrastructure for molecular diag-
nostic to enable systematic HPV detection using generic
Figure 1 HPV genotype prevalence in 483 women with/and without cervical lesions from Northeast Romania. (on the X axis are the
percentages for each category according to the classification IARC for HPV types: HRHPV, PHRHPV, LRHPV; total cases: 483 - except 31/514 cases
with inflammatory cytology) (HR HPV types: High Risk HPV types, pHR HPV: probably High Risk HPV types, LR HPV types: Low Risk HPV types).
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Page 3 of 5tests [9,15,16] followed by genotyping of the positive
samples in regional reference centers. Also, implementa-
tion of a systematic screening program in Romania
using generic cost effective DNA/HPV detection tests,
would further imply an improvement of clinical sensitiv-
ity (cross hybridization with HR genotypes) and specifi-
city (i.e., increase the detection cut-off of the assays) of
screening tests. Also, DNA/HPV tests should be vali-
dated analytically and clinically to be adequate for diag-
nostic use [16].
There is currently an open national cervical cancer
screening pilot study undergoing in Romania. However,
this study is still regional and aims to a 10% coverage
only. These numbers are clearly different from those
observed in other EU countries (i.e., in Netherland the
coverage is 77%). This demonstrate that in order to sig-
nificantly improve the efficacy of cervical cancer screen-
ing there is an important need for education of women
as well as of medical professionals too [17]. At the same
conclusion reached Apostol et al, regarding implement-
ing in Romania of one organized cervical cancer screen-
ing [18]. Arbyn M. et all identified in 2007 the burden
of cervical cancer in Romania requiring implementation
of one well-organized cervical cancer program; the same
authors published in 2010, by joinpoint regression
method that the incidence and mortality through cervi-
cal cancer in Romania is increasing [19,20].
Being a new member of EU, in Romania there are still
challenges regarding starting of one organised pro-
grammes for cervical cancer: the main reason is the lack
of the infrastructure necessary to implement it [21].
Even though our pilot study was carried out on a lim-
ited number of patients, it covered a large number of
patients and generated results that may permit the pol-
icy makers to initiate cervical cancer screening and vac-
cination programs for teenagers.
Conclusions
In developing countries as Romania, HPV testing can be
used in primary cervical cancer screening. This will be
beneficial for patients who will thus avoid excessive
referrals to colposcopy and overtreatment [9,14,22].
In the future, screening via HPV/DNA tests and vacci-
nation must become coordinated, with programs provid-
ing the most cost-effective cervical cancer prevention
strategies.
Our results regarding epidemiological issues are com-
parable with WHO data at global and European level
[6]. Also, they are similar with the overwhelming epide-
miological evidence for the role of sexual activity in the
transmission of anogenital HPV infections [23,24].
The efficiency of prevention programs (screening, vac-
cination) is highest if the aim of these programs is
focused on community needs. In this respect, the high
prevalence of HR HPV documented by our study justi-
fies entirely the necessity of cervical cancer prevention
programs in Romania.
Methods
The study was carried out between September 2009 and
November 2011, and included 514/1896 consecutive
women (aged: 17-84 years, median: 36.5) from the
“Cuza-Vodă” Gynecology Clinical Hospital. All patients
were monitored by clinical gynecological examination,
cytology exam and some of them, by colposcopic
examination.
Women with abnormal Pap smears (ASCUS–Atypical
Squamous Cells of Undetermined Significance,A S C - H –
Atypical Squamous Cells for which a High-grade lesion
cannot be excluded,L G S I L –Low Grade Squamous
Intraepithelial Lesion,H G S I L –High Grade Squamous
Intraepithelial Lesion or inflammatory result) or with
only suggestive colposcopy exam were genotyped for
HPV infection.
Each participant signed an informed consent and the
study was approved by the Bioethical Committee of the
“G r .T .P o p a ” University of Medicine and Pharmacy of
Iaşi, and each woman completed a questionnaire con-
cerning possible cofactors for cervical cancer (e.g.,
smoking, genital coinfections, oral contraceptive use,
number of sex partners), and provided cytological
results of previous Papanicolau tests.
Cervical cells were sampled with a cervical brush and
they were transported in Cobas PCR Cell Collection
Media (Roche). DNA purification was done using the
High Pure PCR Template (Roche); HPV detection was
performed using the Linear Array HPV Detection kit
(Roche), and then DNA was genotyped with the Linear
Array HPV Genotyping Test (Roche, Iaşi, Romania).
Genotyping via this technique involves one step of PCR
amplification (ABI 9700): the final volume contained 50
μl of purified DNA and 50 μlo fm a s t e rm i x( Roche).
The thermal profile included the next steps: HOLD pro-
gram: 2 min/50°C; an initial denaturation of 9 min at
95°C was followed by 40 cycles of 95°C for 30 s, 55°C
for 1 min, and 72°C for 1 min, with a final extension for
7 min at 72°C. The amplicons have been denatured at
the end of PCR amplification.
HPV types were detected by hybridizations of the
amplicons. Hybridization was performed in a TwinCu-
bator (HAIN, Life Science) using Working Hybridization
Buffer, Working Ambient Wash Buffer, Working Strin-
gent Wash Buffer, Working Conjugate, Working Citrate
Buffer and Working Substrate (Roche). The technique
was validated through the use of positive and negative
controls at each shift; the strips contain two bands for
beta globin, which checks if the sample was correctly
processed.
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14 HR HPV (high risk) types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68) and 24 pHR HPV (probably high
risk)a n dL RH P V( low risk) types (6, 11, 26, 39, 40, 42,
45, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81,
82, 83, IS39, CP6108). We validated our HPV genotyp-
ing technique by obtaining proficiency for all the HPV
types included in WHO HPV Proficiency Study, 2010.
For the main HR HPV types (16, 18, 33, 52) we con-
firmed the results of LA genotyping result by qPCR/
MX3005P (Stratagene manufacturers) detection using
quantitative evaluation.
List of abbreviations
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